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Abstract
Growth hormone secretagogue receptor (GHS-R) signaling has been associated
with growth hormone release, increases in food intake and pleiotropic cardio-
vascular effects. Recent data demonstrated that acute GHS-R antagonism leads
to increases in mean arterial pressure mediated by the sympathetic nervous
system in rats; a highly undesirable effect if GHS-R antagonism was to be used
as a therapeutic approach to reducing food intake in an already obese, hyper-
tensive patient population. However, our data in conscious, freely moving
GHS-R deficient mice demonstrate that chronic absence of GHS-R signaling is
protective against obesity-induced hypertension. GHS-R deficiency leads to
reduced systolic blood pressure variability (SBPV); in response to acute high-
fat diet (HFD)-feeding, increases in the sympathetic control of SBPV are sup-
pressed in GHS-R KO mice. Our data further suggest that GHS-R signaling
dampens the immediate HFD-mediated increase in spontaneous baroreflex
sensitivity. In diet-induced obesity, absence of GHS-R signaling leads to
reductions in obesity-mediated hypertension and tachycardia. Collectively, our
findings thus suggest that chronic blockade of GHS-R signaling may not result
in adverse cardiovascular effects in obesity.
Introduction
Ghrelin is an acylated peptide hormone, mainly secreted
from the gastrointestinal mucosa and it functions as the
endogenous ligand to the growth hormone secretagogue
receptor 1a (GHS-R) (Kojima et al. 1999). Although origi-
nally identified as a potent stimulator of pituitary growth
hormone secretion and orexigenic hormone [for review:
(Van Der Lely et al. 2004)], more recently ghrelin’s roles have
extended to include food-reward behaviors and a host of car-
diovascular actions (Perello et al. 2010; Granata et al. 2011).
GHS-Rs are expressed in various CNS areas and periph-
eral tissues. Key CNS sites include nuclei of the mediobasal
hypothalamus, ventral tegmental area of the midbrain and
hindbrain sites, including the nucleus of the solitary tract
(NTS), dorsal motor nucleus of the vagus nerve (DMV)
and area postrema (Zigman et al. 2006). GHS-R expression
has also been reported in heart and blood vessels, although
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the latter may be area- and species-specific (Howard et al.
1996; Gnanapavan et al. 2002; Callaghan et al. 2012).
In addition to inotropic and cardioprotective effects
against ischemia, ghrelin and its mimetics have been
found to exert significant vasodilatory action [for review
see (Granata et al. 2011)]. Studies in humans found that
intravenous (i.v.) injection of ghrelin elicits a decrease in
blood pressure (Nagaya et al. 2001; Lambert et al. 2011),
although these effects of ghrelin and its mimetics are not
always consistent (Bisi et al. 1999). In rabbits, i.v. injec-
tion of ghrelin caused dose-related decreases in mean
arterial pressure (MAP) without significant changes in
renal sympathetic nerve activity (RSNA) (Matsumura
et al. 2002). The hypotensive action of ghrelin was also
confirmed in rats (Li et al. 2009). Additionally, intracere-
broventricular (i.c.v.) injection of ghrelin caused a
significant decrease in MAP, HR, and RSNA, suggesting
that systemically administered ghrelin acts, at least in
part, via the CNS (Matsumura et al. 2002). Indeed, NTS
injections of ghrelin significantly decrease MAP and HR
by suppression of sympathetic nerve activity in rats (Lin
et al. 2004). Longer-term (10-day) i.c.v. infusion of ghre-
lin in rats also cause mild reductions in MAP and HR by
reducing sympathetic tone to the heart, whereas i.v. infu-
sions had no such effect (Freeman et al. 2013). Further-
more, studies with the synthetic GHS-R antagonist
[D-Lys-3]-GHRP-6 showed a significant sympathetic ner-
vous system-mediated, dose-dependent increase in both
HR and MAP in conscious rats (Vlasova et al. 2009).
GHS-R antagonism may be an attractive therapeutic
approach to reducing food intake, however, concomitant
increases in blood pressure in an already obese and most
likely hypertensive patient population is highly undesir-
able. Given discrepancies in the literature on ghrelin’s car-
diovascular actions, in combination with absence of
mechanistic insight into ghrelin’s cardiovascular effects,
we sought to investigate long-term cardiovascular effects
in the absence of GHS-R signaling.
Obesity is a strong, independent risk factor for the
development of cardiovascular disease; indeed 75% of
hypertensive disease is related directly to obesity (Go
et al. 2013). Hypertension itself is a highly significant risk
factor for the development of all manifestations of cardio-
vascular disease, including coronary heart disease, stroke
and heart failure. The etiology of obesity-induced hyper-
tension includes insulin- and leptin-mediated increases in
sympathetic nervous system activity as well as an
increased renin-angiotensin-aldosterone system activity
(Hall et al. 2010). Given ghrelin’s autonomic modulation
of the cardiovascular system, we sought to investigate
GHS-R-mediated roles in obesity-induced hypertension.
Of note, ghrelin- and GHS-R-mediated cardiovascular
effects in rodents have to date been solely investigated
using pharmacological approaches mostly in anaesthetized
animals. In addition, room for a discussion around alter-
native ghrelin receptors remains (Seim et al. 2011).
Here, we investigate the cardiovascular effects of
chronic absence of GHS-R signaling in freely moving, con-
scious, lean and diet-induced obese GHS-R-deficient mice.
Materials and Methods
Animals
Studies were performed in accordance with the UK Ani-
mals (Scientific Procedures) Act 1986 and with approval
of the University of Bristol Ethical Review Group.
Wild-type (WT) and GHS-R null littermate mice on a
C57BL/6J background were obtained from AstraZeneca
(GHS-R1A KO mice originally obtained from Deltagen
(San Carlos, CA, USA); colony maintained from heterozy-
gous breeding pairs) (Egecioglu et al. 2010). Genotyping
was performed at weaning by ear notch PCR, using the
following primer sequences in 50–30: GCTACTTCGC-
CATCTGCTTC (upstream-targeted exon), AAGACGCTC
GACACCCATAC (within-targeted exon) and GGGTGGGA
TTAGATAAATGCCTGCTCT (within-targeting cassette).
On arrival at the University of Bristol, all mice were single-
caged with environmental enrichment (nesting and card-
board tubes). All mice were housed under controlled condi-
tions of temperature (21–22°C), humidity (50%), and
12:12 h light/dark cycle. Mice were placed on a standard
chow diet (2016 Teklad Global 16% Protein Diet; Harlan,
Shardlow, UK) and had free access to tap water.
Telemetry
Male GHS-R knockout and wild-type littermate mice
received radio-telemeter implants (TAIIPA-C10; Data Sci-
ences International, St Paul, MN, USA) in the carotid
artery, as described earlier (Kaidi et al. 2007). In brief,
mice were anaesthetized with 3,3,3-Tribromoethanol
(250 mg/kg; Sigma, Gillingham, UK) and a small incision
was made from the ventral neck. The right common caro-
tid artery was isolated, ligated, and cannulated using the
catheter of the pressure transducer, and further secured
using nonabsorbable sutures (Look 5.0; Harvard Appara-
tus, Edenbridge, UK). The body of the transmitter was
placed in a subcutaneous pocket down the left flank of
the mouse. Mice continued to be singly caged after sur-
gery with environmental enrichment. Freely moving
mouse cardiovascular parameters were monitored on
individual receiver pads after a minimum recovery period
of 10 days post-surgery, typically for 5 min every hour
for 48-h (1000 Hz sampling frequency), using the teleme-
try data acquisitions system (Dataquest A.R.T.TM 4.0; Data
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Sciences International). Measurements were split into
light (9 AM–5 PM), dark (9 PM–5 AM) phase, and average
24 h.
Acute HFD-feeding
Mice (7 month) with radio-telemeter implants were placed
on a high-fat diet (Research Diets D12331, 58 kcal% fat w/
sucrose Surwit Diet, New Brunswick, NJ) for 12 days, dur-
ing which food intake, body weight and cardiovascular
parameters were recorded every other day. Cardiovascular
parameters were recorded during the dark phase (9 PM–
5 AM) for 5 min every hour.
Diet-induced obesity
Mice (7 month) were placed on a high-fat diet (Research
Diets D12331, see above) for 15 weeks prior to telemetry
surgery and weighed weekly. After assessment of fasting
glucose levels (16 h over-night fast) by tail tip and hand-
held glucometer, mice underwent telemetry surgery (as
described above). Cardiovascular parameters were recorded
over a 48-h period, recording for 5 min every hour. Mea-
surements were split into light (9 AM–5 PM), dark (9 PM–
5 AM) phase, and average 24 h.
DSI and statistical analysis
Cardiovascular parameters collected by Dataquest A.R.T
4.0 (Data Sciences International) include mean arterial
pressure (MAP), systolic and diastolic blood pressure
(SBP, DBP), interbeat intervals (IBI) and dPdt (cardiac
contractility).
Power spectral analysis to obtain frequency data for
systolic blood pressure variability (SBPV) analysis were
performed after interpolating SBP and IBI (50 Hz, 2nd
order), detrending and mean suppressing raw data. The
power spectra were divided into two domains: high-
frequency (HF) 1.5–4 Hz and low-frequency (LF) 0.15–
1.5 Hz (Baudrie et al. 2007) and data were normalized
into a Hanning distribution, with one overlapping.
To assess spontaneous baroreflex sensitivity, mean
arterial pressure data were exported into hemolab baro-
reflex analysis software (http://www.haraldstauss.com/
HemoLab/HemoLab.php). The hemolab analyzer identi-
fies rises and falls in MAP and HR, which occur in a lin-
ear fashion and involve three or more consecutive points;
a method previously validated (Moffitt et al. 2005; Stauss
et al. 2006).
Group data are expressed, as mean  SEM. Data were
compared using Student’s t-tests, one- or two-way repeated
measures analyses of variance (ANOVA) followed by Bon-
ferroni’s procedure for multiple comparisons, where
appropriate using GraphPad Prism software (GraphPad
Software, Inc., La Jolla, CA).
CORT measurements
Male 5 months-old WT and GHS-R mice were singly
caged, acclimatized to handling for 3 weeks and on the day
of experiment tail pricked for 10 lL blood collection in
heparinized capillary tubes every 2 h from 8 AM until 22 PM
1:5 dilutions of serum samples were assayed using a Corti-
costerone HS EIA kit (Immunodiagnostic Systems Limited,
Boldon, UK) according to manufacturer’s instruction.
Results
GHS-R deficiency leads to reduced systolic
blood pressure variability
Male, 6-month-old WT and GHS-R KO mice had identi-
cal body weight (WT = 30.49  0.70 g, GHS-R
KO = 30.58  0.19 g). GHS-R deficiency had no effect
on mean arterial pressure (MAP), heart rate (HR) or sys-
tolic blood pressure (SBP) (Fig. 1A–C). Diastolic blood
pressure and cardiac contractility were also unaffected
(data not shown). Circadian rhythmicity of cardiovascular
parameters was maintained independent of GHS-R geno-
type (Fig. 1A–D) and no differences in diurnal corticoste-
rone variations were noted (Fig. 1F). Identifying the
frequency components of blood pressure variability by
power spectral analysis can provide important informa-
tion on blood pressure control mechanisms, which oper-
ate at different response times. In terms of autonomic
control of blood pressure variability, a low-frequency
zone (LF) has been identified, which reflects sympathetic
control, whereas a high-frequency zone (HF) is under
vagal control (Baudrie et al. 2007). Spectral analysis of
systolic blood pressure variability showed a significant
reduction in the LF/HF power ratio in GHS-R KO mice,
which was most prominent over a 24-h period (P < 0.05,
Fig. 1D). Spontaneous baroreflex sensitivity (sBRS) was
unaltered by GHS-R deficiency (Fig. 1E). These data sug-
gest that long-term GHS-R deficiency does not lead to
overt cardiovascular abnormalities, but modulates auto-
nomic control of blood pressure oscillations.
GHS-R deficient mice are resistant to high-
fat diet-mediated increases in systolic blood
pressure variability
During 12 days of high-fat diet (HFD) feeding no differ-
ence in body weight or food intake was observed between
genotypes of adult, 7 month-old male mice. GHS-R KO
and WT mice both reduced average food intake to
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account for increased calorie diet (Fig. 2A). Cardiovascu-
lar parameters were recorded during the dark phase every
other day for 12 days. MAP remained unaltered in
response to acute HFD-feeding in both WT and GHS-R
KO mice. Although HR was slightly elevated in response
to HFD-feeding, this response was identical in WT and
GHS-R KO mice (Fig. 2B).
As described above, SBPV was significantly decreased
in GHS-R KO mice during chow diet-feeding (Fig. 1D);
this phenomenon was exacerbated during acute
HFD-feeding. While in WT mice, SBPV increased
over time of HFD-feeding, this response was absent in
GHS-R KO mice (P < 0.05, Fig. 2C), along with a lack of
increase in sympathetic control of blood pressure oscilla-
tions (LF power, Fig. 2C). sBRS was increased in both
WT and GHS-R KO mice in response to HFD-feeding
(Fig. 2D), however the initial, immediate response was
significantly stronger in GHS-R KO mice (P < 0.05).
Diet-induced obese GHS-R deficient mice
have lower MAP than their WT littermates
despite similar body weights
During longer-term HFD feeding adult, male mice were
weighed every week for 12 weeks prior to surgical
implantation of radio-transmitters. Body weight of GHS-
R KO and WT littermates significantly increased by
47.5% (approximately 15 g, P < 0.01) over the 12-week
period with no difference in body weight gain between
genotypes (Fig. 3A). HFD-fed GHS-R KO and WT mice
had diet-induced obese (DIO) hallmark fasting hypergly-
cemia compared to WT age-matched control chow-fed
mice (P < 0.05, Fig. 3A).
Cardiovascular physiology of these obese WT and GHS-
R KO mice was monitored for a 48-h period. While HR
remained unchanged between genotypes, GHS-R KO mice
had significantly decreased MAP compared to WT litter-
mates, evident particularly during the dark phase
(P < 0.05, Fig. 3B). These data suggest that absence of
ghrelin signaling protects mice from developing DIO-med-
iated hypertension despite significant HFD-mediated
weight gain.
GHS-R deficient mice are protected from
HFD-induced hypertension
To elucidate the cardiovascular physiological differences
between chow, acute and long-term HFD-fed mice, aver-
age dark-phase measurements were compared between
chow, day-12 acute HFD, and chronic HFD-fed mice.
A B
D E F
C
Figure 1. Growth hormone secretagogue receptor (GHS-R) is critical for appropriate regulation of systolic blood pressure variability. Radio-
telemetry measurements in ad libitum chow fed, adult male wild-type (WT, open bars) and GHS-R KO (black bars) littermate mice. (A) Mean arterial
pressure. (B) Heart rate. (C) Systolic blood pressure. (D) Spectral analysis of systolic blood pressure variability as LF/HF ratio. GHS-R signaling is
critical in the maintenance of appropriate autonomic control of blood pressure oscillations. (E) Spontaneous baroreflex sensitivity. Dark phase
(9 PM–5 AM)/light phase (9 AM–5 PM) phase: two-way repeated measures ANOVA for time and genotype, 24 h: t-test; *P < 0.05 for genotype (WT
n = 6; GHS-R KO n = 8). (F) Diurnal corticosterone (CORT) profiles in WT (gray lines) and GHS-R KO (black lines) mice (n = 8).
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Obese chronic HFD-fed WT mice had significantly
increased MAP and HR from chow levels (P < 0.01 and
P < 0.05, respectively, Fig. 4A). However, similarly obese
HFD-fed GHS-R KO mice had no significant alterations
in MAP or HR from chow levels and were thus protected
from obesity-induced hypertension and tachycardia.
Interestingly, in WT mice SBPV increased with acute
HFD-feeding (P < 0.05), but was significantly blunted in
chronic HFD-feeding (P < 0.01 compared to chow and
P < 0.001 compared to acute HFD, Fig. 4B). However, in
GHS-R deficiency no alteration of SBPV was observed in
response to HFD-feeding. sBRS was comparable between
WT and GHS-R KO littermates with increases in response
to acute HFD-feeding (initially exaggerated in GHS-R KO
mice, both genotypes P < 0.001 compared to chow)
which were reduced in chronic HFD-feeding (both geno-
types P < 0.01 compared to acute HFD-feeding, Fig. 4C).
Discussion
Combining radio-telemetry techniques with genetically
modified mouse models, allows the assessment of the
roles of individual genes in long-term regulation of
cardiovascular parameters in freely moving conscious
animals. In contrast to previous studies investigating car-
diovascular pharmacological GHS-R activity modulation,
data here represent the cardiovascular phenotypes result-
ing from long-term GHS-R signaling deficiency. However,
as GHS-R KO mice used in these studies lack GHS-Rs
throughout development and life, mechanisms that may
compensate for the loss of GHS-R signaling may mask
some effects that can be seen with acute GHS-R inhibi-
tion. Ultimately, effects described in GHS-R KO mice are
thus physiological roles of GHS-R signaling that cannot
be compensated for. In addition, GHS-Rs have been
described to have high constitutive activity (Mear et al.
2013) and ablation of this ligand-independent constitutive
activity without affecting ghrelin-mediated GHS-R signal-
ing has significant consequences for stature and weight
alone (Wang et al. 2004). The predictive value of life-long
GHS-R deletion to chronic pharmacological inhibition
thus needs to be viewed with caution.
Consistent with previous reports (Zigman et al. 2005)
GHS-R deficiency did not cause body weight differences
A B
C D
Figure 2. Growth hormone secretagogue receptor (GHS-R) deficient mice are resistant to acute high-fat diet (HFD)-mediated increases in
systolic blood pressure variability. Adult male WT (gray lines) and GHS-R deficient mice (black lines) were fed a HFD for 12 days and dark-phase
cardiovascular parameters recorded every other day. (A) Body weight and food intake over 12-day period. (B) Mean arterial pressure and heart
rate. (C) Spectral analysis of systolic blood pressure variability (LF/HF ratio and HF and LF alone). While in WT mice SBPV increases over time of
HFD-feeding, this response is absent in GHS-R KO, due, in most part, to a lack of increase in sympathetic control of blood pressure oscillations.
(D) Spontaneous baroreflex sensitivity. sBRS is increased in both WT and GHS-R KO mice in response to HFD-feeding, however, this response
appears increased in GHS-R KO mice. Arrow indicates start of HFD-feeding. (two-way ANOVA repeated measures for time and genotype,
*P < 0.05 for genotype, WT n = 6; GHS-R KO n = 7).
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in adult male mice; importantly, cardiovascular effects in
GHS-R deficiency are thus not secondary to body weight
changes. However, as these are global KO mice and the
GHS-R is expressed both centrally and peripherally, it is
not possible to determine the exact tissue origin of effects.
In brief, our data suggest a significant role for
deficiency in GHS-R signaling in the protection against
diet-induced obesity-mediated hypertension, despite con-
siderable diet-mediated weight gain. Protection against
diet-mediated hypertension may be downstream of favor-
able changes in autonomic control mechanisms of blood
pressure variability, including suppression of sympathetic
dominance.
GHS-R signaling is involved in the
maintenance of systolic blood pressure
variability
GHS-R deficiency does not lead to an overt cardiovascu-
lar phenotype, however, spectral analysis of SBP showed
reduced SBPV in GHS-R KO mice. Alterations in SBPV
in GHS-R KO mice may be downstream of an altered
GH/IGF-I axis, as reduced IGF-I levels have been reported
in GHS-R KO mice (Sun et al. 2004). Furthermore, we
cannot exclude the possibility of ghrelin effects mediated
by receptors other than the GHS-R; these have certainly
been described (Benso et al. 2004). However, as ghrelin
levels in GHS-R KO mice have been reported to be nor-
mal (Sun et al. 2004), this is unlikely to have a significant
effect on SBPV differences. An altered stress axis is also
unlikely to contribute to the SBPV effect as GHSR-defi-
cient mice have normal diurnal corticosterone rhythms.
Acute pharmacological inhibition of the GHS-R in con-
scious rats has been shown to lead to increased MAP via
sympathetic nervous system activation (Vlasova et al.
2009), highlighting the potential for different physiologi-
cal responses to acute inhibition versus chronic absence
of GHS-R and perhaps also putative effects of GHS-R
antagonists on other non-GHS-R receptors [e.g., (Patel
et al. 2012)]. Furthermore, i.c.v. ghrelin infusion over
10 days caused mild reductions in MAP and HR, however
no such effect was observed with i.v. infusion, further high-
A
B
Figure 3. Diet-induced obese (DIO) Growth hormone secretagogue receptor (GHS-R) deficient mice have lower MAP than their WT littermates
despite similar body weights. Male adult WT and GHS-R KO mice were fed a HFD for 12 weeks and cardiovascular parameters recorded every
other day. (A) HFD-fed WT and GHS-R KO mice significantly increase in body weight and show fasting hyperglycemia (one-way ANOVA,
*P < 0.05, **P < 0.01, WT chow n = 9, WT HFD n = 10, GHS-R KO n = 9). (B) Radio-telemetry measurements in DIO WT and GHS-R KO
littermate mice after 12 weeks of HFD feeding. GHS-R KO mice have lower MAP than WT littermates despite similar weight gain on HFD. (dark
phase (9 PM–5 AM)/light phase (9 AM–5 PM) two-way repeated measures ANOVA for time and genotype; 24 h t-test; *P < 0.05 for genotype;
WT n = 8; GHS-R KO n = 6).
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lighting ghrelin’s differential effects depending on injection
route (Freeman et al. 2013). In addition, pharmacological
studies using exogenous ghrelin are complicated by its
conversion into des-acyl-ghrelin as well as by effects on
GHS-R-mediated growth hormone release, making com-
parison to data manipulating the endogenous ghrelin
system difficult. Global, long-term deletion of GHS-R sig-
naling has no effect on MAP or HR; our data thus suggest
that longer-term GHS-R antagonism, as for example in a
food intake reducing therapy, may not result in increased
MAP – a strategy that deserves further attention.
Rapid increase in sympathetic control of
SBPV and sBRS in response to HFD feeding,
followed by hypertension, tachycardia, and
onset of other negative prognostic
indicators of cardiovascular disease
Short-term HFD-feeding over 12 days caused immediate,
significant and expected reductions in food intake to
account for increased calorie content of the diet. While
there was no effect on MAP over the 12 days of HFD, the
immediate increase in heart rate is likely part of a stress
response to alteration of the diet; in contrast, chronic
HFD-feeding leads to obesity accompanied by sustained
hypertension and tachycardia. Indeed, diet-induced obes-
ity-mediated effects on the cardiovascular system are well
recognized in humans and rodents alike (Hall et al. 2000;
Esler et al. 2006). Spectral analysis of blood pressure
oscillations revealed immediate, significant increases in
SBPV in response to the diet, driven mainly by an
increase in sympathetic control (LF component) with a
milder concomitant reduction in parasympathetic influ-
ence (HF component). Previous data have suggested that
hypertension is associated with sympathetic dominance
(Esler et al. 2006); our data show that the increase in
sympathetic control of SBPV in response to HFD is
immediate. This autonomic imbalance may over time
drive the hypertension observed with diet-induced obes-
ity. Importantly, sBRS is increased immediately in
response to HFD-feeding, likely in a bid to maintain
MAP in the face of HFD-feeding.
In chronic HFD-feeding, once diet-induced obesity
with concomitant fasting hyperglycemia, hypertension,
and tachycardia has set in, SBPV is significantly sup-
pressed. The initial rise in sBRS is also significantly
blunted in diet-induced obesity, indicating perhaps a fail-
ure to maintain appropriate blood pressure oscillations
and baroreflex control in the face of long-term high-fat
diet exposure. Reduced sBRS has indeed been correlated
A
B C
Figure 4. Growth hormone secretagogue receptor (GHS-R) deficient mice are protected from HFD-induced hypertension. Comparison of dark-
phase cardiovascular phenotypes in mice fed chow (white bars), HFD for 12 days (gray bars) or 12 weeks (black bars). (A) Mean arterial
pressure and heart rate. GHS-R deficient mice are protected against DIO-mediated hypertension and increases in HR. (B) Power spectral analysis
of SBPV. SBPV responses to diet are absent in GHS-R KO mice. (C) Spontaneous baroreflex sensitivity. (two-way ANOVA for diet and genotype;
*P < 0.05, **P < 0.01, ***P < 0.001, WT n = 6–8, KO = 5–8).
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with increased insulin-resistance (Lucini et al. 2006) and
diet-induced obesity in rodents and humans (Dangardt
et al. 2011; Latchman et al. 2011; Fardin et al. 2012;
McCully et al. 2012).
GHS-R deficiency protects from diet-induced
obesity-mediated hypertension
No significant differences in body weight gain were
observed in GHS-R KO mice and their WT littermates
during acute or chronic HFD-feeding. Previous studies
using different strains of GHS-R KO mice have shown
diverse results in terms of body weight responses to
HFD-feeding. Zigman et al. (2005) report that male
GHS-R-deficient mice have no body weight phenotype on
a chow diet, while they are partially protected from diet-
induced obesity when placed on a HFD at 4 weeks of age.
On the other hand, Sun et al. (2008) demonstrate that
male GHS-R KO mice are significantly lighter than their
WT littermates on chow and HFD, but gain similar
amounts of weight during HFD-feeding from 16 weeks of
age; the authors thus argue against GHS-R deficiency pro-
tecting from diet-induced obesity. Different animal mod-
els, background strains, diet compositions and ages of
mice may be to blame for discrepancies between these
and our own studies. In our hands, the equal body weight
gain and development of fasting hyperglycemia in HFD-
fed WT and GHS-R KO mice allows direct comparison of
cardiovascular parameters without metabolic confounds.
Despite significant weight gain, GHS-R deficiency protects
mice from HFD-induced hypertension and tachycardia.
Thus, in contrast to acute, pharmacological GHS-R antag-
onist studies in conscious rats reporting increases in MAP
(Vlasova et al. 2009), we find protective effects of chronic
GHS-R deficiency against obesity-induced hypertension.
Thus, while few and only modest GHS-R antagonist
effects on body weight and food intake have been
described (Xin et al. 2006; Esler et al. 2007; Rudolph
et al. 2007; Puleo et al. 2012), GHS-R antagonism may
provide beneficial cardiovascular effects in obesity.
Our data further suggest that GHS-R signaling is criti-
cally involved in the regulation of SBPV in response to
HFD feeding, with a shift away from sympathetic domi-
nance in the immediate response to HFD-feeding of
GHS-R KO mice. The immediate sBRS response to HFD-
feeding is exaggerated in GHS-R KO mice, indicating per-
haps that peripheral (e.g., blood vessel) GHS-R signaling
may normally act to diminish the baroreflex response,
due to its vasodilatory effects.
Overall, our data demonstrate a significant role for GHS-
R signaling in the autonomic modulation of blood pressure
oscillations, possibly by triggering baroreflex-mediated
sympathoexcitation in HFD-feeding. Previous data have
shown intravenous ghrelin-mediated increases in muscle
sympathetic nerve activity in both lean and obese humans
(Lambert et al. 2011; Krapalis et al. 2012) although i.c.v.
and NTS injections of ghrelin significantly suppressed sym-
pathetic nerve activity in rats (Lin et al. 2004; Freeman et al.
2013). Our data support a role for ghrelin-mediated
increases of sympathetic outflow, which may be down-
stream of peripheral vascular effects, explaining ghrelin’s
differential autonomic effects depending on injection route.
Importantly, sexual dimorphism in HFD-mediated
body weight gain has been noted in male versus female
GHS-R KO mice, with females being more affected by the
diet (Zigman et al. 2005). In future experiments it will be
important to explore whether a sexual dimorphism is also
apparent in cardiovascular responses to GHS-R deficiency,
as this might have significant implications for potential
therapeutic outcomes. Future experiments, using mice
with tissue-/neuronal-subpopulation-specific expression of
GHS-R (Zigman et al. 2005) are needed to determine the
tissue/CNS site responsible for GHS-R deficiency’s protec-
tive effects against the development of hypertension.
Conclusions
In conclusion, we demonstrate a role for GHS-R signaling
in the autonomic regulation of blood pressure variability
in basal states, as well as in response to changes in diet.
We show that absence of GHS-R signaling protects
against obesity-induced hypertension downstream of
favorable changes in autonomic control mechanisms,
including suppression of sympathetic dominance. Future
pharmacological studies will need to identify whether
long-term GHS-R antagonism may have similar beneficial
cardiovascular effects in diet-induced obesity.
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